Name | Enarodustat |
Description | Enarodustat (JTZ-951) is an orally active factor inhibitor of prolyl hydroxylase (EC50: 0.22 μM) and has the potential for renal anemia treatment. |
In vitro | Enarodustat exhibits neither CYP (IC50 > 100 μM; CYP3A4/5, CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2B6) nor hERG (IC50 > 100 μM) inhibition. |
In vivo | Enarodustat [1 and 3 mg/kg, p.o., in rats] treatment increases hemoglobin levels in a dose-dependent manner. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 83.33 mg/mL (244.85 mM), Sonication is recommended.
|
Keywords | HIF/HIF Prolyl-Hydroxylase | HIFs | inhibit | HIF-PH | Hypoxia-inducible factors | Enarodustat | JTZ951 | JTZ 951 | Inhibitor |
Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | 1,4-DPCA | DMOG | Chlorogenic Acid | Roxadustat | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Minocycline hydrochloride | Oltipraz | Glucosamine sulfate |
Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | HIF-1 Signaling Pathway Compound Library | Glutamine Metabolism Compound Library | Anti-Cancer Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max |